TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01168219

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allogeneic hematopoietic stem cell transplantation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-Thymocyte Globulin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given SC or IV
Study: NCT01275209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCD122
Study: NCT01168219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given PO or IV
Study: NCT02872844

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ICS AirCal3
Description: Each patient will undergo a 30-minute heat stress to one ear. For randomization, the left ear will be treated in patients with a registration number ending with an odd number and the right for even numbers. An ICS AirCal3 Research Strategy (Otometrics) system attached to an Intel Core 15vPro Thinkpad (IBM) laptop is used within the audiometry department of a separate outpatient clinic. The patients will be reclined and the hot air caloric at 50°C applied by a licensed, unblinded audiologist for 30 minutes. The patients will be allowed to fixate and use whatever means they prefer for entertainment during the intervention.
Study: NCT00533793

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open fracture reduction
Description: internal fracture fixation: osteosynthesis plates or intra-medullary nails

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open fracture reduction
Description: internal fracture fixation: osteosynthesis plates or intra-medullary nails

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open fracture reduction
Description: internal fracture fixation: osteosynthesis plates or intra-medullary nails

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open fracture reduction
Description: internal fracture fixation: osteosynthesis plates or intra-medullary nails
Study: NCT02816827

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AG-01
Description: Product to increase mental alertness
Study: NCT03122431

Intervention type: DRUG
Group type: OTHER
Intervention: Thalidomide
Description: Thalidomide 100 mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine reduced
Description: Hydroxychloroquine 2.5 mg/kg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard dose of HCQ
Description: Hydroxychloroquine 5.0 mg/kg/day
Study: NCT02816827

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AG-01
Description: Product to increase mental alertness

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AG-05
Description: Product to increase mental alertness

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AG-05
Description: Product to increase mental alertness

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AG-06
Description: Product to increase mental alertness

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AG-06
Description: Product to increase mental alertness

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AG-07
Description: Product to increase mental alertness

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AG-07
Description: Product to increase mental alertness
Study: NCT01385397

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preceptorship and virtual community
Study: NCT02245425

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supine Thoracic Spine Manipulation
Description: Position patient so that small amplitude quick stretch can be applied to the least mobile area of the thoracic spine that is identified during the spinal segmental mobility testing. The thoracic spine thrust manipulation will be applied at an appropriate range of motion as identified by the clinician.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Prone Thoracic Spine Manipulation
Description: Position patient so that small amplitude quick stretch can be applied to the least mobile area of the thoracic spine that is identified during the spinal segmental mobility testing. The thoracic spine thrust manipulation will be applied at an appropriate range of motion as identified by the clinician.
Study: NCT01811056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: Mifepristone use outside of the center
Study: NCT02575547

Intervention type: DRUG
Intervention: cisplatin and docetaxel
Description: NC：cisplatin 75 mg/m2 intravenous infusion in day1，docetaxel 75 mg/m2 intravenous infusion in day1，both drugs are given every 3 weeks, two courses.~CCRT: intensity modulation radiation therapy(IMRT) and cisplatin (100mg/m2 on day 1) every three weeks for three\\three cycles during radiation therapy(RT).~Dietary supplement: enteral nutrition and parenteral nutrition
Study: NCT03154229

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Smartphone-based decision-support
Description: WHO guidelines have been adapted from paper onto a smartphone referred to as a Rehydration Calculator

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Paper-based decision-support
Description: WHO guidelines presented on paper

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pre-Assessment of practices
Description: Observation of baseline clinical practice.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pre-Assessment of practices
Description: Observation of baseline clinical practice.
Study: NCT00458029

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: integrated program of nutrition, activity, behavior, and promotion
Description: implemented across 5 half-year periods: winter/spring 2007, fall 2007, winter/spring 2007, fall 2008, winter/spring 2008
Study: NCT02689921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Aromatase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Aromatase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: Aromatase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Acetate
Description: Luteinizing Hormone-Releasing Hormone agonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Monoclonal antibody (HER2/neu receptor antagonist)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Monoclonal antibody (HER2/neu receptor antagonist)
Study: NCT03968939

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diphenhydramine (Benadryl)
Description: Oral Diphenhydramine (Benadryl), 25 mg

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: Oral Melatonin, 3 mg

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Hygiene Education
Description: Brochure containing information about getting a good night's sleep.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Hygiene Education
Description: Brochure containing information about getting a good night's sleep.
Study: NCT03414892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Globalagliatin Hydrochloride
Description: once daily, oral
Study: NCT00573794

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: adalimumab prefilled syringes administered as subcutaneous injection EW or EOW
Study: NCT02999490

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 18F-FDG
Description: 18F-FDG is positron emission tomography imaging agent which is already widely used in PET/CT examination.
Study: NCT00434135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine plus pemetrexed, paclitaxel plus gemcitabine
Description: gemcitabine 1,250 mg/sqm days 1\&8 + pemetrexed 500 mg/sqm day 8 paclitaxel 120 mg/sqm + gemcitabine 1,000 mg/sqm days 1\&8

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine plus pemetrexed, paclitaxel plus gemcitabine
Description: gemcitabine 1,250 mg/sqm days 1\&8 + pemetrexed 500 mg/sqm day 8 paclitaxel 120 mg/sqm + gemcitabine 1,000 mg/sqm days 1\&8
Study: NCT00639938

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nevirapine
Description: 200 mg Nevirapine tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine
Description: 200 mg Nevirapine tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine
Description: 200 mg Nevirapine tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HIV immune globulin solution
Description: 5% intravenous HIV immune globulin solution
Study: NCT02584192

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: entailing an early home-based CR program
Description: enter the early outpatient phase of CR program. The progressive exercise training of this phase was performed without supervision after their discharge. The CR program consisted of a five-minute warm-up period (stretching), a twenty-minute aerobic exercise (walking or trotting, gymnastics), and a five-minute cooling-down period (stretching)

Intervention type: OTHER
Group type: OTHER
Intervention: enter the usual care program
Description: enter the usual care program, including the importance of carrying out physical activity, which was performed during inpatient care.
Study: NCT01563887

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DD.com
Description: Internet intervention in which participants will complete 6 Cores, or classes over the internet, focusing on risk factors and prevention, detection, and management of hypoglycemia before and while driving.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DD.com + MI
Description: Prior to starting and immediately after finishing the DiabetesDriving.com internet intervention, a one hour motivational interview will be conducted with participants. Internet intervention in which participants will complete 6 Cores, or classes over the internet, focusing on risk factors and prevention, detection, and management of hypoglycemia before and while driving.
Study: NCT01044186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICL670
Study: NCT03961711

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Telemedicine
Description: Patients will undergo a Telemedicine encounter with the physician at the 3-week post-operative timepoint following a total hip or total knee arthroplasty.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: In-Person Clinic Visit
Description: Patients will undergo an in-person clinic encounter with the physician at the 3-week post-operative timepoint following a total hip or total knee arthroplasty.
Study: NCT01116544

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AMES Therapy (assisted movement and enhanced sensation)
Description: Each subject will receive 30 sessions of AMES therapy in the clinic. Each session will consist of 10 min of functional testing (i.e., passive motion and strength tests) followed by 30 min of grasp therapy using the AMES device. One group of subjects will receive AMES therapy only with joint torque biofeedback (without EMG feedback), and the other group will receive AMES therapy with EMG biofeedback. While all test subjects should attempt to open the hand when the grasp mechanism is opening and close the hand when the mechanism is closing, the biofeedback information provided to aid a subject will differ for the 2 subject groups.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AMES Therapy (assisted movement and enhanced sensation)
Description: Each subject will receive 30 sessions of AMES therapy in the clinic. Each session will consist of 10 min of functional testing (i.e., passive motion and strength tests) followed by 30 min of grasp therapy using the AMES device. One group of subjects will receive AMES therapy only with joint torque biofeedback (without EMG feedback), and the other group will receive AMES therapy with EMG biofeedback. While all test subjects should attempt to open the hand when the grasp mechanism is opening and close the hand when the mechanism is closing, the biofeedback information provided to aid a subject will differ for the 2 subject groups.
Study: NCT04416880

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Press Tack Needle Acupuncture
Description: Seirin Pyonex Press Tack Needle 0.20 x 0.60 mm for SI1 Shaoze acupuncture point Seirin Pyonex Press Tack Needle 0.20 x 0.90 mm for CV17 Danzhong acupuncture point

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Press Tack Needle Acupuncture
Description: Seirin Pyonex Press Tack Needle 0.20 x 0.60 mm for SI1 Shaoze acupuncture point Seirin Pyonex Press Tack Needle 0.20 x 0.90 mm for CV17 Danzhong acupuncture point
Study: NCT04396899

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: EHM implantation
Description: Implantation of EHM on dysfunctional left or right ventricular myocardium in patients with HFrEF (EF \<35%).
Study: NCT05268406

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C-Scan System
Description: Subjects will be provided with contrast agent and dietary fiber pills, and instructed to start intake approximately 48 hours prior to the planned C-Scan procedure start. C-Scan system intervention includes ingestion of the C-Scan Cap and attachment of the C-Scan track to the subject's lower back. The subject is required to keep the C-Scan Track attached to the lower back and to continue intake of contrast agent and dietary fiber pills until the C-Scan Cap's natural excretion. Standard of care optical colonoscopy will be performed within 60 days from the C-Scan Cap ingestion.
Study: NCT00930215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D961H
Description: Oral gelatin capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D961H
Description: Oral HPMC capsule
Study: NCT03449264

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: biological collection
Description: * Tissue samples (tumor tissue and healthy tissue) frozen and secured in paraffin collected during surgery.~* Blood samples taken at different times. During the blood samples taken for diagnosis and / or treatment, additional samples for research purposes will be carried out.
Study: NCT01725750

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bright White Light (BWL)
Description: Participants will self-administer bright white light daily. Litebooks used for Bright White Light and Dim Red Light are identical except for the light which they emit. Users are instructed to place it about 18 from their face and within 45º of the visual field for 30 minutes within half an hour of waking each morning, for 4 weeks. The participant may eat, read, watch TV, etc. while sitting in front of the box.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dim Red Light (DRL)
Description: A device that appears identical to BWL Litebook but that uses red LEDs emitting DRL. Users are instructed to place it about 18 from their face and within 45º of the visual field for 30 minutes within half an hour of waking each morning, for 4 weeks. The participant may eat, read, watch TV, etc. while sitting in front of the box.
Study: NCT00982904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexinidazole/Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fexinidazole/Placebo
Study: NCT02542072

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: comfilcon A
Description: contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: samfilcon A
Description: contact lens
Study: NCT04241965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-214870
Description: Tablet(s)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: OPC-214870
Description: Tablet(s)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablet(s)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet(s)
Study: NCT01502904

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus-eluting stent
Description: 2x2 randomization by the treatment of dyslipidemia and hypertension(In patients of dyslipidemia: pitavastatin 2mg/day vs. pravastatin 20mg/day, in patients of hypertension: eporsartan 600mg/day vs. Non-ARB) and the types of the implanted DES, SES vs BES.
Study: NCT02393157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal ARA-C
Description: Will be given intrathecally for both prophylaxis and treatment of CNS disease.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal ARA-C
Description: Will be given intrathecally for both prophylaxis and treatment of CNS disease.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Ifosfamide 3000 mg/m2/day as a 2 hour IV infusion daily x 3 days (Days 0,1,2) of Cycle 1 and 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Ifosfamide 3000 mg/m2/day as a 2 hour IV infusion daily x 3 days (Days 0,1,2) of Cycle 1 and 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin: 635 mg/m2 as 1 hour IV infusion on Day 0 only of Cycle 1 and 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin: 635 mg/m2 as 1 hour IV infusion on Day 0 only of Cycle 1 and 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide: 100 mg/m2/day as 1 hour IV infusion daily x 3 days (Days 0,1,2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide: 100 mg/m2/day as 1 hour IV infusion daily x 3 days (Days 0,1,2).
Study: NCT01220076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamoxifen
Study: NCT01502904

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biolimus-eluting stents
Description: 2x2 randomization by the treatment of dyslipidemia and hypertension(In patients of dyslipidemia: pitavastatin 2mg/day vs. pravastatin 20mg/day, in patients of hypertension: eporsartan 600mg/day vs. Non-ARB) and the types of the implanted DES, SES vs BES.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pravastatin 20mg/day after DES implantation
Description: 2x2 randomization by the treatment of dyslipidemia and hypertension(In patients of dyslipidemia: pitavastatin 2mg/day vs. pravastatin 20mg/day, in patients of hypertension: eporsartan 600mg/day vs. Non-ARB) and the types of the implanted DES, SES vs BES.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pitavastatin 2mg/day after DES implantation
Description: 2x2 randomization by the treatment of dyslipidemia and hypertension(In patients of dyslipidemia: pitavastatin 2mg/day vs. pravastatin 20mg/day, in patients of hypertension: eporsartan 600mg/day vs. Non-ARB) and the types of the implanted DES, SES vs BES.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Non-ARB /day after DES implantation
Description: 2x2 randomization by the treatment of dyslipidemia and hypertension(In patients of dyslipidemia: pitavastatin 2mg/day vs. pravastatin 20mg/day, in patients of hypertension: eporsartan 600mg/day vs. Non-ARB) and the types of the implanted DES, SES vs BES.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eposartan 600mg/day after DES implantation
Description: 2x2 randomization by the treatment of dyslipidemia and hypertension(In patients of dyslipidemia: pitavastatin 2mg/day vs. pravastatin 20mg/day, in patients of hypertension: eporsartan 600mg/day vs. Non-ARB) and the types of the implanted DES, SES vs BES.
Study: NCT01032148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBH589
Description: LBH589 will be administered orally as once daily dose of 20 mg po q M, W, F on a q28 day cycle.
Study: NCT02901431

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants received a matching placebo orally. Approximate treatment duration was up to 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5285119
Description: Participants received age-adjusted total daily oral dose approximately equivalent to the adult doses of either 4 mg/d or 10 mg/d of balovaptan (RO5285119). Approximate treatment duration was up to 24 weeks (up to 52 additional weeks for those enrolled in the OLE).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5285119
Description: Participants received age-adjusted total daily oral dose approximately equivalent to the adult doses of either 4 mg/d or 10 mg/d of balovaptan (RO5285119). Approximate treatment duration was up to 24 weeks (up to 52 additional weeks for those enrolled in the OLE).
Study: NCT00289107

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total Knee Arthroplasty
Description: Rotating Platform (RP) Cruciate Substituting Knee System

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total knee replacement
Description: Fixed Cruciate Substituting Knee System
Study: NCT03414892

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once daily, oral
Study: NCT04055428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacubitril, Valsartan 97-103 mg Oral Tablet
Description: The subject will be randomized, in a double-blind manner to sacubitril/valsartan 97/103 mg twice daily for a period of 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan 160 mg
Description: The subject will be randomized, in a double-blind manner to valsartan 160 mg twice daily for a period of 12 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intravenous Glucose Tolerance Test
Description: An assessment of the insulin sensitivity will be done using the IVGTT, at baseline and after 12 weeks of pharmacological interventions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Glucose Tolerance Test
Description: An assessment of the insulin sensitivity will be done using the IVGTT, at baseline and after 12 weeks of pharmacological interventions.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Standardized Meals
Description: Participants will consume the standardized study mixed meal for the assessment of postprandial GLP-1 response to the meal.